Impact of COVID-19 vaccine doses and viral waves on inflammatory and

immunological responses to COVID-19 infections in India

Kamal Kant Sharma[1,], Uttara Partap[2], Yogesh Marathe[1], Sanaa Shaikh[1], Pradeep D'Costa[3],

Gaurav Gupta[4], Molin Wang[5,6], Wafaie W Fawzi[2,5,7], Kevin C Kain[8], Nerges Mistry[1], Yatin

Dholakia[1]

Affiliations:

[1]The Foundation for Medical Research, Mumbai, India

[2]Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston,

Massachusetts, USA

[3]King Edward Memorial Hospital and Research Centre, Pune, India

[4]Saifee Hospital, Mumbai, India

[5]Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts,

USA

[6]Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

[7]Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

[8]Department of Medicine, University of Toronto and University Health Network, Toronto, Ontario,

Canada

Corresponding author:

Dr. Yatin Dholakia

The Foundation for Medical Research

Dr. Kantilal J. Sheth Memorial Building

84-A, R.G. Thadani Marg

Worli, Mumbai 400 018, India

yatindholakia@gmail.com, Contact Number: +91 22 2493 4989

Abstract:

Background: Investigation of the effect of SARS-CoV-2 variants and COVID-19 vaccination on inflammatory and immune response to SARS-CoV-2 infection is limited in South Asia.

Objectives: We aimed to examine the impact of COVID-19 vaccination and waves of COVID-19 on inflammatory and immunological biomarkers among COVID-19 patients in India.

Methods: This cross-sectional analysis used baseline data from a randomized controlled trial of vitamin D and zinc during COVID-19 infection in India (N=181). Blood samples and data regarding vaccination doses were collected. The second (Delta) or third (Omicron) wave was determined by date of enrolment. Mixed effects linear regression with robust standard errors was used to examine associations between COVID-19 vaccination dose or wave at enrolment and C-Reactive Protein (CRP), ferritin, lactate dehydrogenase (LDH), D-dimer, interleukin-6 (IL-6), angiopoietin-2 (Ang-2), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), immunoglobulin G (IgG) and immunoglobulin M (IgM).

Results: Compared to no vaccination, full vaccination was associated with lower LDH ($P<0.001$), D-dimer ($P=0.521$) and Ang-2 ($P=0.046$), and higher IgG levels ($P<0.001$). Partial vaccination was associated with lower IL-6 ($P=0.040$) and higher IgG ($P<0.001$). Enrolment during the third wave was associated with lower IL-6 ($P<0.001$), CRP ($P=0.056$), IgM ($P=0.013$), and IgG ($P<0.001$), but higher D-dimer levels ($P<0.001$).

Conclusions: COVID-19 vaccination status and SARS-CoV-2 variant influence the inflammatory and immunologic response during SARS-CoV-2 infection, contributing to the severity of clinical presentation.

Keywords: COVID-19, vaccine, variants, inflammation, immunology, biomarkers

Tables: 4, Figures: 0

Word count: 3762 (Introduction: 420, Discussion: 1346), Abstract: 223

Competing interests:

All authors declare no conflicts of interest.

Registration:

Clinical Trial Registry of India (CTRI): CTRI/2021/04/032593

(https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NTQ1MTA=&Enc=&userName=CTRI

/2021/04/032593)

Ethical approval:

This study was conducted in accordance with the Declaration of Helsinki, and informed

written consent was taken from study participants. Ethical approval was obtained from the

Institutional Review Board of the Harvard T.H. Chan School of Public Health (Protocol No.

IRB20-1425), the University Health Network Research Ethics Board (20-5775), the

Institutional Research Ethics Committee of the Foundation for Medical Research (IREC No.

FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No.

EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No.

2027).

Author contributions:

KKS, UP, WWF, KCK, YD, and NM conceptualized the study along with YM, SS, PD, GG and

MW. KKS, YD, YM, SS, PD and GG were involved in data acquisition, and in study monitoring

along with KCK, WWF, NM and UP. MW provided statistical expertise. KKS and UP analysed

the data, KKS drafted the first draft of manuscript, and all authors reviewed and critically

revised the draft and approved the final manuscript. (Contributors' form is included in

supplementary material)

Introduction

Introduction

COVID-19 infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-

CoV-2), a major global health concern of the 21st century, and has affected more than 609

million people and caused over 6.5 million deaths worldwide.[1] The ability of SARS-CoV-2

viruses to undergo frequent and random mutations may result in the development of highly

contagious and lethal variants, and this has extended the COVID-19 pandemic through

multiple waves of infection.[1]

The progression of COVID-19 infection is associated with altered clinical manifestations and

changes in the level of related inflammatory and immunological biomarkers. Innate immune

responses, coagulation, and the initiation of pro-inflammatory responses are common

pathways to counteract infectious agents, which may result in increased circulating levels of

acute phase proteins such as C-reactive protein (CRP), ferritin, and D-Dimer. In particularly

acute cases, the proliferation of the virus in the host cell and its rapid spread in other cells

results in a cytokine storm, which is considered a critical condition.[2] The profile of human

immune response, transmission ability, laboratory characteristics, and antigenicity of the

virus depends at least partially on the COVID-19 virus variant.[3,4] While differences in

symptoms have been noted,[5] there are limited data available on inflammatory and

immunological responses to different SARS-CoV-2 variants, particularly from South Asian

populations.

Protective immunity through vaccines was paramount to reducing the severity of COVID-19

disease and breaking the chain of transmission. India also scaled up its domestic vaccine

research and development program for the launch of the vaccination drive in the country by

January 2021 and has achieved over 2 billion vaccinations so far.[6] Around 921 million

people had their first dose of the COVID-19 vaccine in India, 863 million were fully

vaccinated (2 doses), and around 139 million received their precautionary dose by

September 2022.[7] It has been observed that vaccination and its doses directly impact the

inflammatory and antibody response to SARS-CoV-2 infection.[8,9] However, evidence

regarding the effect of COVID-19 vaccination on the inflammatory and immunological

response among newly-infected patients remains limited, particularly from lower- and

middle-income populations such as those in South Asia.[10]

Few data have been reported on a comprehensive range of inflammatory and

immunological markers by COVID-19 vaccination doses and second versus third waves of

the COVID-19 pandemic (which roughly correspond to two distinct SARS-CoV-2 variants –

Delta and Omicron respectively) from COVID-19 patients, particularly in India. In this study,

we aimed to determine the association between COVID-19 vaccination doses and waves of

COVID-19, and a set of inflammatory and immunological biomarkers, among SARS-CoV-2-

infected patients in Maharashtra, India.

Materials and Methods

Study procedures

This analysis uses baseline data from a randomized controlled trial aiming to evaluate the effects of vitamin D and zinc supplementation on COVID-19 outcomes in Maharashtra, India (ClinicalTrials.gov registration: NCT04641195).[11] From April 2021 to February 2022, hospitalized or home-isolated COVID-19 patients aged ≥18 years with a positive RT-PCR or rapid antigen test and with mild to moderate symptoms were enrolled from two study sites: King Edward Memorial (KEM) Hospital and Research Centre, Pune, and Saifee Hospital, Mumbai.

Details regarding study procedures have been outlined previously,[11] baseline procedures are briefly described as follows. At enrolment, background information, medical history, and clinical symptoms were obtained and clinical assessment was conducted along with the collection of blood samples for routine laboratory investigations and study of specific inflammatory and immunological biomarkers. In addition, participants were asked about details of their COVID-19 vaccination status at baseline and during successive follow-ups. Routine blood investigation included testing of CRP, lactate dehydrogenase (LDH), serum ferritin, and D-dimer. This was performed at the respective hospital sites, which were accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). All COVID-19 treatment, such as medications, was delivered by clinicians independently of the study, guided by the national treatment recommendations for COVID-19 at the time.[12]

Testing of other plasma biomarkers including angiopoietin-2 (Ang2), interleukin-6 (IL-6), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), immunoglobulin G (IgG),

and immunoglobulin M (IgM) were conducted at the coordinating institute, The Foundation

for Medical Research (FMR). Blood samples collected were processed at hospital sites for

plasma, and the centrifuged matrix was transported to FMR adhering to the transportation

regulations provided by the Government of India (GOI) for COVID-19 samples.[13] Aliquots of

plasma were prepared for further testing and stored at -20°C. The concentration of

biomarkers was quantified using sandwich enzyme-linked immunosorbent assay (ELISA),

was performed according to the manufacturer's instructions; Thermofisher Invitrogen, USA

(IL-6, Ang-2, sTREM-1) and RayBiotech, USA (IgG and IgM) and readings were observed at

450 nm. Due to issues with the sample kit, sTREM-1 assays were performed only for a

subset of 48 participants. To ensure accurate results, the samples were run in triplicates.

<u>Variables of interest</u>

Exposures of interest were COVID-19 vaccination status and wave during which the

participant was enrolled. Participants were categorized based on their COVID-19 vaccination

doses received till the day of enrolment. Participants with no COVID-19 vaccine were

grouped as unvaccinated, those with one dose were partially vaccinated, and those who

received second dose and/or the final third (precautionary or booster) dose were

categorized as fully vaccinated. Participants were enrolled across two waves of the COVID-

19 pandemic in India. These waves were defined as wave 2 (predominantly Delta; enrolled

from the start of the study in April 2021 to 15th December 2021), and wave 3

(predominantly Omicron; enrolled from 21st December 2021, onwards – no participants

were enrolled between 15th-21st December 2021).[14]

Outcomes of interest were the following inflammatory and immunological biomarkers:

serum CRP, LDH, and ferritin, plasma D dimer, IL-6, Ang2, sTREM-1, IgG, and IgM. As part of

the analysis, we considered other potentially important participant characteristics including

sex, age, education, health behaviour (smoking and alcohol consumption), pre-existing

medical conditions, COVID-19 medication, body mass index (BMI), COVID-19 vaccine type,

median number of days with symptoms and median days since last vaccine dose before

enrolment.

<u>Statistical analysis</u>

First, baseline demographic, clinical, health behaviour, COVID-19 medication, and

anthropometric characteristics were compared across the two exposures of interest: 1)

COVID-19 vaccination and 2) COVID-19 waves. Differences between groups were examined

by Pearson's Chi-squared tests or Fisher's exact tests (comparisons with cell counts <5) for

categorical variables, and Wilcoxon rank sum tests or Kruskal Wallis tests (comparisons

across >2 groups) for continuous variables. We also examined median biomarker levels

across the two exposures of interest, testing for differences across groups using Wilcoxon

rank sum tests or Kruskal Wallis tests, as described above.

Following this, effects of the exposures of interest on each outcome were modelled using

mixed-effects linear regression with robust standard errors. Models were adjusted for the

other exposure (either COVID-19 vaccination or wave), and for age, sex, health behaviour

(smoking and alcohol consumption), pre-existing medical conditions, COVID-19 medication,

BMI, COVID-19 vaccine type, and median number of days with symptoms and were

additionally adjusted for clustering at the hospital site level. Although we also initially

included days since last vaccination in regression models, this variable was dropped due to

collinearity with the COVID-19 vaccination variable. Missing observations for covariates

were minimal (maximum: 2 participants [1.1%] for any covariate) and we assumed these

were missing completely at random. We used the missing indicator method to handle

missing data in regression models. All analyses were performed using STATA, version 14.1

(StataCorp, Texas).

<u>Ethics</u>

The procedures followed in this study were in accordance with the ethical standards of all

responsible ethical committees listed below, and with the Declaration of Helsinki, and

informed written consent was taken from study participants. Ethical approval was obtained

from the Institutional Review Board of the Harvard T.H. Chan School of Public Health

(Protocol No. IRB20-1425), the University Health Network Research Ethics Board (20-5775),

the Institutional Research Ethics Committee of the Foundation for Medical Research (IREC

No. FMR/IREC/C19/02/2020), the Institutional Review Board of Saifee Hospital (Project No.

EC/008/2020) and the KEM Hospital Research Centre Ethics Committee (KEMHRC ID No.

2027). The trial is registered on ClincialTrials.gov: NCT04641195, and Clinical Trial Registry of

India (CTRI): CTRI/2021/04/032593. Health Ministry Steering Committee (HSMC) - GOI

endorsement was received before the commencement of the study.

Results

Overall baseline and clinical characteristics of the enrolled participants

Total 181 COVID-19 patients were included in the study. The mean (SD) age of the study participants was 47 (15.7) years, and the range was 18-87 years. One-fourth of participants (24.8%) were 60 years of age or older. The proportion of male participants was 51.3%, and 91.8% of participants had received secondary or higher-level education. Around 62% of participants were overweight or obese (30.9% in each category), only 6 individuals (3.3%) were underweight and a normal BMI was found in 34.8% participants. The median (interquartile range [IQR]) number of days with symptoms before enrolment was 3 days (2-4). 39.7% of participants reported comorbidities such as hypertension (24.8%), diabetes (20.9%), and cardiovascular disease (7.7%), and 19.8% of participants were on any COVID-19 medications. Among the antiviral medications, Remdesivir was used the most frequently (12.2%) (Table 1).

Baseline characteristics of the enrolled participants across exposure variables (vaccination status and waves of COVID-19 pandemic in India)

At the time of enrolment, one-fifth (19.9%) of individuals were unvaccinated, 13.3% had their first dose of COVID-19 vaccine, and 51.9% patients enrolled were fully vaccinated with two or three doses; 14.9% did not provide information on their vaccination status. The median days since last vaccine dose before enrolment was 126 days (IQR: 51-216). Fifty-eight percent individuals received COVISHIELD vaccine by AstraZeneca and Serum Institute of India, 7.1% received COVAXIN (Bharat Biotech) which was approved and introduced later, 19.9% were unvaccinated at the time of enrolment, and rest around 15% did not provide their vaccination details (Table 1).

A greater proportion of unvaccinated and fully vaccinated individuals was male (*P*=0.049).

Additionally, a greater proportion of partially vaccinated individuals was in 30-44 years age

group (*P*=0.008), had graduate education (*P*=0.006), was enrolled during the second wave

(*P*<0.001), and was using any COVID-19 medications (*P*=0.061). Full vaccination was

common in older participants who were more than 44 years, and among those who

reported hypertension (*P*=0.023), any pre-existing conditions, and obesity. The median days

from last dose before enrolment in partially vaccinated participants was 61 days (IQR: 31-

92) while it was 167 ([range 77-241] days for the fully vaccinated group (*P*<0.001)) (Table 1).

Most (66.3%) of the study participants were enrolled during the second wave. A larger

proportion of participants who enrolled in the second wave were aged 30-44 years

(*P*=0.381), and had normal BMI compared to third wave participants (*P*=0.019). All

participants enrolled in the third wave had secondary or higher education whereas about

one tenth of those enrolled in the second wave had primary or less education (*P*=0.004).

Close to half (46%) of participants enrolled in the third wave were obese, compared with

23.3% of participants enrolled in the second wave (Table 1).

Levels of inflammatory and immunological biomarkers of COVID-19 infected participants

across vaccination status and waves of COVID-19 (unadjusted analyses)

We first compared unadjusted median biomarker levels across vaccination status at

enrolment and the COVID-19 wave in which the participants were enrolled. The unadjusted

median CRP, LDH, ferritin, D-dimer and IL-6 levels were lower in fully and partially

vaccinated groups as compared to the unvaccinated group (*P*<0.001 for LDH and IL-6, and *P*=

0.005 for ferritin). The unadjusted levels of other inflammatory markers Ang-2 and sTREM-1

were higher in both vaccinated groups than unvaccinated group, but not significant

(*P*=0.454 and *P*=0.977 respectively). Unadjusted IgG levels were significantly elevated in

vaccinated groups as compared to the unvaccinated group especially in partially vaccinated

people (*P*=0.009), while unadjusted IgM levels were also notably high in partially vaccinated

group and lower in fully vaccinated people (*P*=0.014) (Table 2).

The study participants enrolled in the second wave had a higher median level of unadjusted

CRP, LDH, ferritin, and IL-6 compared to individuals enrolled in the third wave (*P*<0.05 for

all). These participants also had lower unadjusted median D-dimer levels, though this was

not significant (*P*=0.155). Furthermore, unadjusted plasma levels of IgM and IgG antibodies

were significantly lower in the third wave compared with second wave participants (*P*<0.001

and *P*=0.019 respectively) (Table 2).

Regression analysis of effect of vaccination status and wave of COVID-19 pandemic on

inflammatory and immunological biomarkers (adjusted analyses)

In fully-adjusted multivariable regression models, full vaccination (but not partial

vaccination) was associated with lower LDH and Ang-2; LDH (β: -77.4, 95% CI: -89.3 – -65.4,

P<0.001) and Ang-2 (β: -61.0, 95%CI: -121.0 – -1.0, *P*=0.046) respectively. Full vaccination

was also associated with lower D-dimer levels, but the association did not reach statistical

significance (β: -248.9, 95% CI:-1,009.4 – 511.7, *P*=0.521). Furthermore, partial and full

vaccination was associated with lower IL-6 levels as compared to no vaccination, with

similar magnitudes of difference for both groups but significant associations only for the

partially vaccinated group (β: -41.8, 95% CI: -81.7 – -1.9, *P*=0.040). In a subset of the cohort,

in fully vaccinated participants had higher sTREM-1 levels (β:72.6, 95% CI: 70.6–74.5,

P<0.001) (Table 3).

Although not significant, decreasing trends in CRP in partially vaccinated (β: -26.1, 95% CI: -

102.1 – 50.0, *P*=0.502) and fully vaccinated individuals (β: -28.5, 95% CI: -88.0 – 30.9,

P=0.347) were observed, similarly decreasing ferritin levels in partial and fully vaccinated

participants were also noticed (β: -38.7, 95% CI: -439.6– 362.2, *P*=0.850 and β: -177.4, 95%

CI: -691.3 – 336.5, *P*=0.499 respectively) (Table 3).

Significant associations between partial and full vaccination and elevated IgG were detected

(β: 61.5, 95% CI: 48.9 – 74.1, *P*<0.001, and β: 62.2, 95% CI: 56.7 – 67.6, *P*<0.001

respectively). Estimates suggested increased levels of IgM associated with partial

vaccination. However, these estimates of increase were not significant, and were also not

statistically different from estimates for fully-vaccinated individuals, with fully overlapping

confidence intervals (Table 3).

Additionally, in these fully-adjusted analyses, enrolment in the third wave was associated

with significantly lower IL-6 (β: -12.0, 95% CI: -12.6 – -11.4, *P*<0.001), and CRP which was

borderline significant (β: -21.7, 95% CI: -44.0 – 0.6, *P*= 0.056). On the other hand, higher D-

dimer values were significantly associated with enrolment in third-wave (β: 322.5, 95% CI:

80.9 – 564.2, *P*=0.009). Other inflammatory markers including ferritin, LDH, and Ang-2 levels

were also lower in third-wave versus second-wave participants, but differences in these

biomarkers were not significant (Table 4).

Significant lower IgG and IgM were associated with enrolment in the third wave as

compared to second-wave; IgM (β: -23.6, 95% CI: -42.3 – -4.9, *P*= 0.013) and IgG (β: -77.6,

95% CI: -99.4 – -55.8, *P*<0.001) (Table 4).

Discussion

In this study, we found that levels of inflammatory markers, particularly LDH and Ang-2 were significantly lower in fully vaccinated participants compared to unvaccinated participants with COVID-19. Furthermore, we observed some evidence of lower IL-6 levels in both partially and fully vaccinated participants, and substantially elevated IgG levels in both partially and fully vaccinated participants. We also found that infection during the third wave was associated with lower CRP, IL-6, and IgG levels, and higher D-Dimer levels.

Inflammation is a defence mechanism that is activated by a coordinated signalling pathway, and also regulates inflammatory mediator levels in host tissue cells and inflammatory cells recruited from the blood.[15] Previous studies have shown that vaccinated patients have reduced severity of COVID-19 disease compared to unvaccinated patients, and individuals with different vaccination doses have variable immune-inflammatory characteristics including the existence of higher neutralizing antibodies response and lower inflammatory markers.[16,17]

CRP LDH, ferritin, D-dimer, and IL-6 are inflammatory markers explored commonly in COVID-19 and other research studies. However, evidence on the association between COVID-19 vaccination and variants and other inflammatory markers such as Ang-2 and sTREM-1, as performed in our study, is scarce – we were unable to find any relevant studies during our search of the literature on these associations. Some previous studies, including from South Asia, have examined the relation between COVID-19 vaccination or variants and commonly measured inflammatory and immunological markers.[10,18,19] Similar to our study, data from these previous reports suggest generally inverse associations between vaccination against COVID-19 and commonly measured inflammatory markers, and positive associations

between vaccination and immunological markers[10,18,19]. For example, an observational

study conducted in Pakistan on a cohort of 434 COVID-19 patients reported significantly

higher LDH, ferritin, and D-dimer levels in unvaccinated individuals compared to vaccinated

individuals.[18] In another study comparing unvaccinated COVID-19 patients with the fully

vaccinated group, significantly lower levels of IL-6 along with CRP and D-dimer were

reported in the fully vaccinated group. This study also showed noticeably higher IgG in fully

vaccinated individuals.[19] Similarly, significantly higher IgG levels among partially vaccinated

individuals were also observed in our study.

Also corroborating our results, a recent observational study conducted in India on 1160

hospitalized COVID-19 patients found similar trends of immunological and inflammatory

biomarkers. This included raised D-Dimer levels reported after the first vaccination, but

lower levels after 2 or 3 doses, and non-significant declining CRP.[10] Taken together with

these previous data, the lower CRP, LDH, ferritin, D-dimer, Ang-2, and IL-6 inflammatory

mediators among vaccinated individuals in our study add to the evidence that vaccine-

induced protection with higher immunological mediators may help to reduce inflammation,

which has been associated with more severe clinical outcomes in COVID-19.[20]

Previous evidence also suggests that the SARS-CoV-2 Omicron variant is less severe

compared to other variants, and limited data from previous reports suggest that the

Omicron variant may induce a smaller inflammatory and immune response.[8,21,22] The

possible reasons noted are less effective replication in the lung parenchyma,[23] and

sustained conservation of T-cell mediated immunity from previous infection or

vaccination.[24] A study conducted in Australia assessed severity of COVID-19 variants

through laboratory findings, and observed lower inflammatory markers, particularly ferritin,

LDH, and CRP levels, linked with Omicron variant compared to Delta variant. This study also

found no significant differences in D-dimer levels.[8] A recent comparative study of the three

waves of COVID-19 in India reported that infection with the Omicron variant versus Delta

variant was associated with significantly lower levels of CRP and IL-6.[21] Another study

conducted in Bangladesh reported higher levels of IgG, and higher risk of hospitalization and

oxygen support were associated with infection with the Delta compared to Omicron

variant.[22] Contributing to growing evidence suggesting that the Omicron variant is

associated with less severe disease, our study also suggests that participants enrolled in

waves of infection corresponding to the Omicron variant had lower inflammatory and

immunological biomarkers.

Contrary to other inflammatory biomarkers, D-dimer concentration in our study was

substantially higher in the third wave compared to the second wave participants. A study on

D-dimer levels suggested that early management of infection with steroids and

anticoagulants in the second wave may affect the production of D-dimer and limit the

endothelial damage, however, only a few participants were on steroids and anticoagulants

in our study.[25] Other reasons could be greater proportion of elderly individuals and high

BMI reported in the third wave in our study which are independent risk factors of high D-

dimer levels.[26,27] Importantly, we adjusted for these factors in analyses, suggesting that

other unmeasured clinical factors may underlie the observed associations.

The immune response is a dynamic process that might also change the inflammatory

parameters. Inflammatory response increases rapidly during the initial phase of infection

and falls during the recovery period, therefore, longitudinal changes in inflammatory

markers are more important rather than values of biomarkers at a single time point.[28]

Typically, after the onset of symptoms, immunological markers IgM and IgG can be detected

during the first week and at around two weeks respectively,[29] and gradually these

antibodies decline with time. The current study suggests that antibodies were higher among

vaccinated participants who later became ill with COVID-19 compared with unvaccinated

individuals. Particularly IgG antibodies remained high even after receiving two or three

vaccine doses compared to those who did not receive any vaccine doses. Together with

recent evidence from India indicating the effect of IgG levels on COVID-19-related measures

such as viral emission[30] these findings help characterize the biological effects of COVID-19

vaccination that may underlie disease severity and outcomes among SARS-CoV-2-infected

individuals.

This study has a few limitations. Information on prior COVID-19 infection was not collected

from the study participants which could affect in the vaccine-induced immune response and

its impact on inflammatory biomarkers. Secondly, different types of COVID-19 vaccines can

elicit diverse antibody responses, although in this study most (89%) of participants had

received the adenoviral vector vaccine (COVISHIELD) in comparison to the whole cell

inactivated virus (COVAXIN). Additionally, genome sequencing for confirmation of COVID-19

variants was not performed in this study, and classification of two waves of the COVID-19

pandemic was made based on defined time points by the federal COVID-19 task forces and

previous research articles.[14] Therefore, there is the possibility that participants enrolled at

beginning of the third wave may have been infected with either the Delta or the Omicron

variant of the SARS-CoV-2 virus. Analyses were based on a small sample size, particularly for

unvaccinated individuals in the third wave – which was likely due to good uptake of vaccines

during the study period. This may have limited our ability to detect associations in certain

cases, as evidenced by the wide confidence intervals for linear regression estimates.

Additionally, this study was based among individuals with mild-to-moderate COVID-19

symptoms and no severe outcomes, meaning that we were unable to clearly examine the

effect of vaccination status, wave of enrolment, and biomarker levels on clinical outcomes.

The foremost strength of this study is the diverse set of inflammatory and immunological

biomarkers of COVID-19 infection explored, which gives an opportunity to understand the

biological changes related to infection that are affected by prior COVID-19 vaccination and

by SARS-CoV-2 variants. Furthermore, we were able to account for a range of potential

demographic, clinical and health-related confounders by adjusting for these in final

regression models. Changes in trends cross unadjusted and adjusted analyses suggested the

importance of accounting for these characteristics when drawing conclusions regarding the

potential effect of vaccination status and COVID-19 wave on biomarker levels. Additionally,

this study also provides indicative data on the different clinical manifestations of two SARS-

CoV-2 variants of concern. The study setting in India enables applicability of findings to the

wider South Asia context where evidence on the effect of COVID-19 vaccine and SARS-CoV-2

variants on inflammatory and immunological responses to SARS-CoV-2 infection remains

scarce.

Conclusion

This study indicates that the inflammatory and immunologic response to SARS-CoV-2

infection may be least partly associated with prior COVID-19 vaccination status and with the

SARS-CoV-2 variant. This study provides data outlining potential pathways through which

COVID-19 vaccination may protect against, and SARS-CoV-2 variants may influence, the

likelihood of severe disease.

References

1. WHO. COVID-19 Weekly Epidemiological Update: Edition 122 Published 14 December
2022. Geneva: World Health Organization; 2022.

2. Hong LZ, Shou ZX, Zheng DM, Jin X. The most important biomarker associated with
coagulation and inflammation among COVID-19 patients. Mol Cell Biochem
2021;476(7):2877–85.

3. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-
CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol
2021;19(7):409–24.

4. Davies MA, Kassanjee R, Rousseau P, Morden E, Johnson L, Solomon W, et al.
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth
wave compared with previous waves in the Western Cape Province, South Africa. Trop
Med Int Health 2022;27(6):564–73.

5. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom
prevalence, duration, and risk of hospital admission in individuals infected with SARS-
CoV-2 during periods of omicron and delta variant dominance: a prospective
observational study from the ZOE COVID Study. The Lancet 2022;399(10335):1618–24.

6. Ministry of Health and Family Welfare. CoWIN [Internet]. 2022 [cited 2023 Mar
9];Available from: https://www.cowin.gov.in/

7. Ministry of Health and Family Welfare. Cumulative Coverage Report of COVID-19
Vaccination - 28 September 2022. New Delhi: Ministry of Health and Family Welfare,
Government of India; 2022.

8. Wang J, Choy KW, Lim HY, Ho P. Laboratory markers of severity across three COVID-19
outbreaks in Australia: has Omicron and vaccinations changed disease presentation?
Intern Emerg Med 2023;18(1):43–52.

9. Brown PE, Fu SH, Bansal A, Newcombe L, Colwill K, Mailhot G, et al. Omicron BA.1/1.1
SARS-CoV-2 Infection among Vaccinated Canadian Adults. N Engl J Med
2022;386(24):2337–9.

10. Munigela A, Sowpati DT, M S, Banu S, Siva AB, V JK, et al. Clinical outcomes in
individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been
vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). IJID Reg 2022;5:104–10.

11. Sharma KK, Partap U, Mistry N, Marathe Y, Wang M, Shaikh S, et al. Randomised trial to
determine the effect of vitamin D and zinc supplementation for improving treatment
outcomes among patients with COVID-19 in India: trial protocol. BMJ Open
2022;12(8):e061301.

12.   MOHFW, GOI. Clinical Management Protocol for COVID-19 (In Adults) - Version 6
432   (24.05.21) [Internet]. New Delhi: Ministry of Health and Family Welfare, Government
433   of India; 2021 [cited 2022 Feb 28]. Available from:
434   https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVI
435   D19adultsdated24052021.pdf

436   13.   Indian Council for Medical Research, National Institute of Virology. Specimen
437   Collection, Packaging and Transport Guidelines for 2019 novel Coronavirus (2019-
438   nCoV) [Internet]. New Delhi: Ministry of Health and Family Welfare, Government of
439   India; 2020 [cited 2023 Mar 9]. Available from:
440   https://www.mohfw.gov.in/pdf/5Sample%20collection_packaging%20%202019-
441   nCoV.pdf

442   14.   Mahajan NN, Kesarwani S, Salunke C, Kumbhar P, Yenkure P, Shaikh J, et al. Clinical
443   presentation, pregnancy complications, and outcomes of pregnant women with
444   COVID-19 during the Omicron-dominant third wave in Mumbai, India. Int J Gynecol
445   Obstet 2022;159(3):968–73.

446   15.   Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb
447   Perspect Biol 2009;1(6):a001651.

448   16.   Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination
449   reduces need for emergency care in breakthrough COVID-19 infections: A multicenter
450   cohort study. Lancet Reg Health Am 2021;4:100065.

451   17.   Gupta N, Kaur H, Yadav PD, Mukhopadhyay L, Sahay RR, Kumar A, et al. Clinical
452   Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough
453   Infections during the Second Wave among the Various States of India. Viruses
454   2021;13(9):1782.

455   18.   Fatima S, Zafar A, Afzal H, Ejaz T, Shamim S, Saleemi S, et al. COVID-19 infection among
456   vaccinated and unvaccinated: Does it make any difference? PloS One
457   2022;17(7):e0270485.

458   19.   Wang C, Li Y, Pan Y, Zhou L, Zhang X, Wei Y, et al. Clinical and immune response
459   characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a
460   retrospective study. J Zhejiang Univ Sci B 2022;23(11):899–914.

461   20.   Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore SC, et
462   al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-
463   CSF in severe COVID-19. Sci Immunol 2021;6(57):eabg9873.

464   21.   Singh S, Sharma A, Gupta A, Joshi M, Aggarwal A, Soni N, et al. Demographic
465   comparison of the first, second and third waves of COVID-19 in a tertiary care hospital
466   at Jaipur, India. Lung India Off Organ Indian Chest Soc 2022;39(6):525–31.

467   22.   Ghosh AK, Landt O, Yeasmin M, Sharif M, Ratul RH, Molla MA, et al. Clinical
468   Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected
469   with the Delta or Omicron Variants of SARS-CoV-2. Vaccines 2022;10(11):1959.

23. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2 Omicron
variant replication in human bronchus and lung ex vivo. Nature 2022;603(7902):715–
20.

24. Choi SJ, Kim DU, Noh JY, Kim S, Park SH, Jeong HW, et al. T cell epitopes in SARS-CoV-2
proteins are substantially conserved in the Omicron variant. Cell Mol Immunol
2022;19(3):447–8.

25. Porfidia A, Porceddu E, Talerico R, Montalto M, Landi F, Pola R. Second wave of the
COVID-19 pandemic: D-dimer levels are not so high anymore. J Thromb Thrombolysis
2021;52(3):779–81.

26. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with
age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J
2007;37(9):607–13.

27. Tita-Nwa F, Bos A, Adjei A, Ershler WB, Longo DL, Ferrucci L. Correlates of D-dimer in
older persons. Aging Clin Exp Res 2010;22(1):20–3.

28. Kim MJ, Lee EB, Song YW, Park JK. Profile of common inflammatory markers in
treatment-naïve patients with systemic rheumatic diseases. Clin Rheumatol
2020;39(10):2899–906.

29. Lau CS, Phua SK, Liang YL, Oh HML, Aw TC. Robust SARS-CoV-2 Antibody Responses in
Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19
Vaccine. Vaccines 2021;9(11):1241.

30. Sriraman K, Shaikh A, Vaswani S, Mestry T, Patel G, Sakthivel S, et al. Impact of COVID-
19 vaccination on transmission risk of breakthrough infections: Lessons from adapted
N95 mask sampling for emerging variants and interventions. J Med Virol
2023;95(1):e28188.

Tables

Table 1. Baseline characteristics of enrolled participants (N=181).

N (%)

	Overall (181)	COVID-19 Vaccination status				P	COVID -19 Waves		P
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
Sex n (%)									
Female	88 (48.6)	17(47.2)	12(50.0)	46(48.9)	13(48.1)	0.049	54(45.0)	34(55.7)	0.172
Male	93 (51.3)	19(52.8)	12(50.0)	48(51.1)	14(51.9)		66(55.0)	27(44.3)	
Age, years, n (%)									
18-29	30 (16.5)	5(13.9)	3(12.5)	13(13.8)	9(33.3)		19(15.8)	11(18.0)	
30-44	55 (30.3)	18(50.0)	12(50.0)	19(20.2)	6(22.2)	0.008	41(34.2)	14(23.0)	0.381
45-59	51 (28.1)	9(25.0)	5(20.8)	31(33.0)	6(22.2)		30(25.0)	21(34.4)	
≥60	45 (24.8)	4(11.1)	4(16.7)	31(33.0)	6(22.2)		30(25.0)	15(24.6)	
Education, n (%)									
Illiterate, no formal, Primary	15 (8.2)	8(22.2)	1(4.2)	3(3.2)	3(11.1)		15(12.5)	0(0.0)	
Secondary or senior secondary	54 (29.8)	8(22.2)	5(20.8)	34(36.2)	7(25.9)	0.006	36(30.0)	18(29.5)	
Graduate	65 (35.9)	8(22.2)	12(50.0)	36(38.3)	9(33.3)		36(30.0)	29(47.5)	0.004
Post-graduate	45 (24.8)	12(33.3)	6(25.0)	19(20.2)	8(29.6)		32(26.7)	13(21.3)	
Missing	2 (1.1)	0(0.0)	0(0.0)	2(2.1)	0(0.0)		1(0.8)	1(1.6)	
Health Behaviour, n (%)									
Smoking	8 (4.4)	2(5.6)	0(0.0)	5(5.3)	1(3.7)	0.736	7(5.8)	1(1.6)	0.270
Current alcohol use (n=180)	19 (10.6)	2(5.6)	3(12.5)	13(14.0)	1(3.7)	0.427	10(8.33)	9(14.75)	0.189
Missing alcohol (n=1)	1(0)	0(0.0)	0(0.0)	1(1.06)	0(0.0)		1(0.83)	0(0)	
Pre-existing conditions, n (%)									
Hypertension	45 (24.8)	4(11.1)	4(16.7)	31(33.0)	6(22.2)	0.023	28(23.3)	17(27.9)	0.505

Table 1. Baseline characteristics of enrolled participants (N=181).

N (%)

	Overall (181)	COVID-19 Vaccination status				P	COVID -19 Waves		P
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
Diabetes	38 (20.9)	9(25.0)	3(12.5)	22(23.4)	4(14.8)	0.472	26(21.7)	12(19.7)	0.755
Heart disease	14 (7.7)	3(8.3)	1(4.2)	7(7.5)	3(11.1)	0.911	11(9.2)	3(4.9)	0.389
Asthma	7 (3.8)	2(5.6)	0(0.0)	4(4.3)	1(3.7)	0.605	4(3.3)	3(4.9)	0.689
Neurological conditions	4 (2.2)	1(2.8)	0(0.0)	0(0.0)	3(11.1)	0.390	3(2.5)	1(1.6)	1.000
Chronic kidney disease	3 (1.6)	2(5.6)	0(0.0)	1(1.1)	0(0.0)	0.200	2(1.7)	1(1.6)	1.000
Chronic obstructive pulmonary disease	1 (0.5)	1(2.8)	0(0.0)	0(0.0)	0(0.0)	0.390	1(0.8)	0(0.0)	1.000
Other (Thyroid ,TB , cancer etc)	8 (4.4)	3(8.3)	1(4.2)	2(2.1)	2(7.4)	0.131	6(5.0)	2(3.3)	0.719
Any pre-existing condition	72 (39.7)	13(36.1)	7(29.2)	43(45.7)	9(33.3)	0.270	49(40.8)	23(37.7)	0.684
COVID-19 medication, n (%)									
Favipiravir	3 (1.6)	1(2.8)	0(0.0)	2(2.1)	0(0.0)	1.000	3(2.5)	0(0.0)	0.552
Remdesivir	22(12.2)	1(2.8)	4(16.7)	15(16.0)	2(7.4)	0.101	16(13.3)	6(9.8)	0.496
Dexamethasone	1 (0.5)	0(0.0)	0(0.0)	1(1.1)	0(0.0)	1.000	1(0.8)	0(0.0)	1.000
Monoclonal antibodies	8 (4.4)	1(2.8)	2(8.3)	5(5.3)	0(0.0)	0.765	8(6.7)	0(0.0)	0.053
Molnupiravir	5 (2.8)	0(0.0)	1(4.2)	4(4.3)	0(0.0)	0.541	0(0.0)	5(8.2)	0.004
Clexan	1 (0.5)	0(0.0)	0(0.0)	1(1.1)	0(0.0)	1.000	0(0.0)	1(1.6)	0.337
Any COVID-19 Medication	36 (19.8)	3(8.3)	7(29.2)	24(25.5)	2(7.4)	0.061	25(20.8)	11(18.0)	0.655
BMI (kg/m², n (%)									
<18.5	6 (3.3)	1(2.8)	2(8.3)	2(2.1)	1(3.7)		4(3.3)	2(3.3)	
18.5-24.9	63 (34.8)	13(36.1)	9(37.5)	29(30.9)	12(44.4)	0.473	46(38.3)	17(27.9)	0.019
25-29.9	56 (30.9)	13(36.1)	6(25.0)	26(27.7)	11(40.7)		42(35.0)	14(23.0)	

Table 1. Baseline characteristics of enrolled participants (N=181).

N (%)

	Overall (181)	COVID-19 Vaccination status				P	COVID -19 Waves		P
		Unvaccinated n=36	Partially vaccinated n=24	Fully vaccinated n=94	Missing n=27		Second wave n=120	Third wave n=61	
≥30	56 (30.9)	9(25.0)	7(29.2)	37(39.4)	3(11.1)		28(23.3)	28(45.9)	
Median number of days with symptoms (IQR)	3 (2-4)	3(2-5)	3(2-5)	2(2-3)	4(2-6)	0.154	3 (2-5)	2 (2-3)	0.105
COVID-19 waves during enrolment, n (%)									
Second wave[1]	120 (66.3)	35(97.2)	19(79.2)	40(42.6)	26(96.3)	<0.001	-		
Third wave[1]	61 (33.7)	1(2.8)	5(20.8)	54(57.5)	1(3.7)				
COVID-19 vaccination status, n (%)									
Unvaccinated	36(19.9)						35(29.2)	1(1.6)	
First Dose	24(13.3)	--					19(15.8)	5(8.2)	<0.001
Second /Booster dose	94(51.9)						40(33.3)	54(88.5)	
Missing	27(14.9)						26(21.7)	1(1.6)	
Median days of last vaccine dose before enrolment (IQR) (n=118)	126 (51-216)	-	61 (31-92)	167 (77-241)	-	<0.001	85 (45-169)	201 (111-274)	<0.001
COVID-19 vaccine type n (%)									
Covishield (AstraZeneca and SII)	105 (58.1)	-	22(91.7)	83(88.3)	-		50(41.7)	55(90.2)	
Covaxin (Bharat Biotech)	13 (7.1)	-	2(8.3)	11(11.7)	-	0.482	9 (7.5)	4(6.6)	0.119
Unvaccinated at enrolment	36 (19.9)	36 (100)	-	-	-		35(29.1)	1(1.6)	
Missing	27(14.9)	-	-	-	27(100.0)		26(21.7)	1(1.6)	

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

Differences between categories were tested using Pearson's Chi-squared tests (Fisher's exact tests for cell count < 5) for categorical variables and Wilcoxon rank sum tests used for continuous variables.

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

Table 2. Median (interquartile range) levels of inflammatory and immunological biomarkers overall and across participant characteristics.

	Inflammatory markers							Immunological markers	
	CRP (mg/L) (N=176)	LDH (IU/L) (N=154)	Serum Ferritin (ng/ml) (N=160)	D-dimer (ng/ml) (N=168)	IL-6 (pg/ml) (N=178)	Ang-2 (pg/ml) (N=178)	sTREM-1 (pg/ml) (N=48)	IgM (U/mL) (N=177)	IgG (U/mL) (N=177)
Overall median, IQR	13.4 (5.0-34.6)	244 (199-321)	153 (61-311)	426 (291-670)	5.1 (2.7-10.5)	1,198 (848-1,690)	148 (66-148)	3.1 (1.1-7.0)	7.1 (0.6-86.8)
Vaccination status									
Unvaccinated	24.1 (5.4-50.6)	290 (220-342)	215 (124-490)	450 (319-718)	9.0 (4.0-13.7)	1,012 (770-1,703)	144 (27-188)	3.3 (1.3-5.9)	1.2 (0.4-98.3)
Partially Vaccinated	14.1 (5.6-39.6)	297 (217-338)	112 (65-515)	475 (288-768)	5.1 (2.5-9.0)	1,226 (933-1,544)	145 (68-169)	5.4 (1.7-14.2)	31.2 (5.3-165.5)
Fully Vaccinated	12.2 (4.6-34.9)	225 (186-274)	124 (43-215)	372 (274-573)	4.3 (2.3-7.4)	1,238 (913-1,646)	150 (23-283)	1.9 (0.8-4.9)	7.5 (1.0-63.5)
P	**0.504**	**<0.001**	**0.005**	**0.202**	**<0.001**	**0.454**	**0.977**	**0.014**	**0.009**
COVID-19 wave									
Second wave[2]	16.2 (5.4-50.6)	271 (205-337)	194 (102-461)	468 (288-744)	6.1 (2.2-10.7)	1,130 (767-1,736)	148 (66-184)	5.3 (2.2-10.7)	13.8 (1.0-110.9)
Third wave[3]	9.9 (4.5-26.0)	225 (191-276)	101 (32-169)	381 (296-515)	4.1 (0.5-2.3)	1,286 (1,000-1,590)	-	1.4 (0.5-2.3)	3.2 (0.5-16.5)
P	**0.028**	**0.014**	**<0.001**	**0.155**	**0.008**	**0.322**	**-**	**<0.001**	**0.019**

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

IQR: interquartile range.

Unadjusted medians (IQR) are reported for all biomarkers (please refer to Tables 3 and 4 for adjusted analyses).

P values are based on Wilcoxon's rank sum test (2 groups), or Kruskal Wallis test (multiple groups).

The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.

Table 3. Estimates of association between COVID-19 vaccination status and inflammatory and immunological biomarkers.

	β Coefficient (95% Conf. Interval)	P
CRP (mg/L)		
Partially vaccinated	-26.1 (-102.1-50.0)	0.502
Fully Vaccinated	-28.5 (-88.0-30.9)	0.347
LDH (IU/L)		
Partially vaccinated	9.3 (-31.7-50.2)	0.658
Fully Vaccinated	-77.4 (-89.3--65.4)	<0.001
Serum Ferritin (ng/ml)		
Partially vaccinated	-38.7 (-439.6-362.2)	0.850
Fully Vaccinated	-177.4 (-691.3-336.5)	0.499
D-Dimer (ng/ml)		
Partially vaccinated	95.4 (-450.3-641.2)	0.732
Fully Vaccinated	-248.9 (-1,009.4-511.7)	0.521
IL-6 (pg/ml)		
Partially vaccinated	-41.8 (-81.7--1.9)	0.040
Fully Vaccinated	-36.3 (-81.4-8.9)	0.116
Angiopoietin-2 (pg/ml)		
Partially vaccinated	1.5 (-379.9-382.9)	0.994
Fully Vaccinated	-61.0 (-121.0--1.0)	0.046
sTREM-1 (pg/ml)		
Partially vaccinated	16.5 (-91.4-124.3)	0.765
Fully Vaccinated	72.6 (70.6-74.5)	<0.001
IgM (U/mL)		
Partially vaccinated	52.7 (-145.7-251.0)	0.603
Fully Vaccinated	-13.9 (-43.6-15.9)	0.360
IgG (U/mL)		
Partially vaccinated	61.5 (48.9-74.1)	<0.001
Fully Vaccinated	62.2 (56.7-67.6)	<0.001

Unvaccinated: received no doses of COVID-19 vaccine. Partially vaccinated: received 1 dose of COVID-19 vaccine. Fully vaccinated: received 2 or 3 doses of COVID-19 vaccine.

95% CI: 95% confidence interval.

Estimates based on mixed effect regression models with robust standard errors.

The comparison group in the model is unvaccinated participants.

The model is adjusted for wave enrolled, age, gender, type of vaccine, BMI, COVID medications, pre-existing diseases, days of symptoms, health behaviour (drinking and smoking), and clustered by hospital sites.

Table 4. Estimates of association between COVID -19 waves and inflammatory and immunological biomarkers.

	β Coefficient (95% Conf. Interval)	P
CRP (mg/L)		
Enrolled wave 3	-21.7 (-44.0-0.6)	0.056
LDH (IU/L)		
Enrolled wave 3	-14.4 (-30.8-1.9)	0.084
Serum ferritin (ng/ml)		
Enrolled wave 3	-29.1 (-171.1-112.9)	0.688
D-Dimer (ng/ml)		
Enrolled wave 3	322.5 (80.9-564.2)	0.009
IL-6 (pg/ml)		
Enrolled wave 3	-12.0 (-12.6--11.4)	<0.001
Angiopoietin-2 (pg/ml)		
Enrolled wave 3	-26.5 (-139.1-86.0)	0.644
sTREM-1 (pg/ml)		
Enrolled wave 3	--	--
IgM (U/mL)		
Enrolled wave 3	-23.6 (-42.3--4.9)	0.013
IgG (U/mL)		
Enrolled wave 3	-77.6 (-99.4--55.8)	<0.001

95% CI: 95% confidence interval.
Estimates based on mixed effects regression models with robust standard errors
The comparison group is wave 2 participants
The model is adjusted for age, gender, vaccination status (unvaccinated: 0 doses of COVID-19 vaccine, partially vaccinated: 1 dose, fully vaccinated: 2 or 3 doses) and type of vaccine, BMI, COVID medications, pre-existing diseases, days of symptoms, health behaviour (drinking and smoking), and clustered by hospital sites.
The second wave of the COVID-19 pandemic in India was defined as the period spanning approximately April 2021 (when study enrolment began) to December 15th, 2021. The third wave was defined as the period spanning from December 21st, 2021, onwards.